Book contents
- Frontmatter
- Contents
- Editors
- Contributors
- Foreword
- Preface
- Introduction
- Completing an audit project
- I Disorders
- II Legislation
- III Physical health
- IV Record-keeping
- V Service provision
- VI Training
- VII Treatment
- 73 Alcohol withdrawal: management
- 74 Anticholinesterase inhibitors: monitoring of cardiac side-effects
- 75 Anticholinesterase inhibitors: prescribing
- 76 Antimuscarinic medications
- 77 Antipsychotics: combined and high dose
- 78 Antipsychotics: prescribing
- 79 Antipsychotics: use in dementia
- 80 Attention-deficit hyperactivity disorder: prescribing
- 81 Atypical antipsychotics: monitoring
- 82 Behavioural problems in adults with intellectual disabilities: medication management
- 83 Benzodiazepines in old age psychiatry
- 84 Covert administration of medication
- 85 Depot antipsychotics: side-effects
- 86 Diazepam as rescue medication in epilepsy
- 87 Electroconvulsive therapy: facilities
- 88 Electroconvulsive therapy: indications
- 89 Hypnotics
- 90 Lithium: monitoring
- 91 Medicines reconciliation
- 92 Mood stabilisers: monitoring
- 93 Nurses’ administration of medication
- 94 Prescribing: British National Formulary limits
- 95 Prescribing: Mental Capacity Act
- 96 Prescribing: p.r.n. medication
- 97 Prescription charts
- 98 Psychological therapies
- 99 Psychotherapy re-referrals
- 100 Psychotropic prescriptions in dual diagnosis
- 101 Rapid tranquillisation
- Appendices
81 - Atypical antipsychotics: monitoring
from VII - Treatment
Published online by Cambridge University Press: 02 January 2018
- Frontmatter
- Contents
- Editors
- Contributors
- Foreword
- Preface
- Introduction
- Completing an audit project
- I Disorders
- II Legislation
- III Physical health
- IV Record-keeping
- V Service provision
- VI Training
- VII Treatment
- 73 Alcohol withdrawal: management
- 74 Anticholinesterase inhibitors: monitoring of cardiac side-effects
- 75 Anticholinesterase inhibitors: prescribing
- 76 Antimuscarinic medications
- 77 Antipsychotics: combined and high dose
- 78 Antipsychotics: prescribing
- 79 Antipsychotics: use in dementia
- 80 Attention-deficit hyperactivity disorder: prescribing
- 81 Atypical antipsychotics: monitoring
- 82 Behavioural problems in adults with intellectual disabilities: medication management
- 83 Benzodiazepines in old age psychiatry
- 84 Covert administration of medication
- 85 Depot antipsychotics: side-effects
- 86 Diazepam as rescue medication in epilepsy
- 87 Electroconvulsive therapy: facilities
- 88 Electroconvulsive therapy: indications
- 89 Hypnotics
- 90 Lithium: monitoring
- 91 Medicines reconciliation
- 92 Mood stabilisers: monitoring
- 93 Nurses’ administration of medication
- 94 Prescribing: British National Formulary limits
- 95 Prescribing: Mental Capacity Act
- 96 Prescribing: p.r.n. medication
- 97 Prescription charts
- 98 Psychological therapies
- 99 Psychotherapy re-referrals
- 100 Psychotropic prescriptions in dual diagnosis
- 101 Rapid tranquillisation
- Appendices
Summary
Setting
This audit is of relevance to all in-patient and out-patient settings. It was originally conducted in an in-patient child and adolescent intellectual disability setting.
Background
Antipsychotics are widely used for severe psychiatric disorders and for managing aggressive behaviours and anxiety related to autism. First-generation antipsychotics, while considered effective, are associated with serious acute and chronic side-effects that frequently limit their use. Second-generation antipsychotics are considered to be equally effective and are sometimes better tolerated. However, these newer antipsychotics are associated with metabolic side-effects, such as weight gain, hyperglycaemia, new-onset diabetes and dyslipidaemia. As these metabolic side-effects are so closely associated with the development of cardiovascular disease, monitoring and early intervention are crucial.
Standards
Standards were taken from the Maudsley guidelines (Taylor et al, 2007), which advise on recommended monitoring requirements for second-generation antipsychotic medication at baseline and follow-up:
ᐅ Baseline assessment should include full-blood count, and determination of HbA1c, urea and electrolytes, fasting lipid and fasting glucose levels, liver function tests, weight and blood pressure.
ᐅ Specific drugs require additional baseline tests:
▹ serum prolactin for amisulpride, olanzapine, risperidone and zotepine
▹ electrocardiography (ECG) for clozapine and zotepine
▹ thyroid function tests for quetiapine.
ᐅ Assessment after 6–12 months should include full blood count, and determination of HbA1c, urea and electrolytes, fasting lipid and fasting glucose levels, liver function tests, weight and blood pressure.
ᐅ Specific drugs require additional follow-up tests:
▹ serum prolactin levels if symptoms arise when using amisulpride, olanzapine, risperidone or zotepine
▹ annual full blood count for olanzapine, ziprasidone and aripiprazole
▹ measurement of creatine phosphokinase levels where symptoms of neuroleptic malignant syndrome arise
▹ annual thyroid function tests for quetiapine.
Method
Data collection
ᐅ An audit tool facilitated data collection. It was designed for easy recording of the name of antipsychotic used, date prescribed, and whether general and specific baseline and follow-up standards had been met.
ᐅ Data were collected from the medical notes and drug charts of patients.
Data analysis
The percentage of patients who had met each of the standards was calculated.
- Type
- Chapter
- Information
- 101 Recipes for Audit in Psychiatry , pp. 193 - 194Publisher: Royal College of PsychiatristsPrint publication year: 2011